New drugs and therapies have become indispensable for treating an array of cancers. Unfortunately, they can also cause damage to the heart, a side effect that has led to the development of a new ...

While statins can reduce LDL levels and ASCVD events, high Lp(a) poses an independent risk that will need attention, too.

As a wave of patent expirations encroaches upon many of the world’s top drugmakers, companies will need to be diligent in ...

SAN ANTONIO -- Research presented at the ObesityWeek annual meeting included studies on rationing of prescription medications ...

With an array of new medicines and medical devices on display, global medical companies are looking to tap further into the ...

"China market is one of the most attractive markets for Edwards," said Leo Tam, senior director of the business unit of Transcatheter Aortic Valve Replacement, Edwards Lifesciences China, citing a lot ...

With full confidence in China, where Novartis recorded 17 percent growth last year, one of the fastest among all major ...

Unsupervised use of hallucinogens like LSD is high, posing significant risks. However, LSD is being clinically tested for treating anxiety and so far seems effective.

The failure to use steroids “breaks your heart” because data show their impact on “really ... and he’s seen less risk for ...

This would be made possible by eight or nine drugs with multi ... used to treat heart failure. "We also expect sales and ...

Novartis expects to increase its annual sales by least 5% per year in the coming years, CEO Vas Narasimhan said in an ...

The global market for Drug Device Combination Products was estimated at US$114.8 Billion in 2023 and is projected to reach US$158.7 Billion by 2030, growing at a CAGR of 4.7% from 2023 to 2030. This ...